Načítá se...
β‐Adrenoceptor activation affects galectin‐3 as a biomarker and therapeutic target in heart disease
Myocardial fibrosis is a key histopathological component that drives the progression of heart disease leading to heart failure and constitutes a therapeutic target. Recent preclinical and clinical studies have implicated galectin‐3 (Gal‐3) as a pro‐fibrotic molecule and a biomarker of heart disease...
Uloženo v:
| Vydáno v: | Br J Pharmacol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6592856/ https://ncbi.nlm.nih.gov/pubmed/30756388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14620 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|